Vornorexant, also known by its developmental code names ORN-0829 and TS-142, is an orexin antagonist medication which is under development for the treatment of insomnia and sleep apnea. It is a dual orexin OX1 and OX2 receptor antagonist (DORA). The medication is taken by mouth. As of June 2021, vornorexant is in phase 2 clinical trials for insomnia and phase 1 trials for sleep apnea. It is under development by Taisho Pharmaceutical.
Property | Value |
---|---|
dbo:abstract |
|
dbo:casNumber |
|
dbo:class | |
dbo:fdaUniiCode |
|
dbo:pubchem |
|
dbo:thumbnail | |
dbo:wikiPageExternalLink | |
dbo:wikiPageID |
|
dbo:wikiPageLength |
|
dbo:wikiPageRevisionID |
|
dbo:wikiPageWikiLink |
|
dbp:c |
|
dbp:casNumber |
|
dbp:chemspiderid |
|
dbp:class | |
dbp:eliminationHalfLife |
|
dbp:f |
|
dbp:h |
|
dbp:iupacName |
|
dbp:n |
|
dbp:o |
|
dbp:pubchem |
|
dbp:routesOfAdministration | |
dbp:smiles |
|
dbp:stdinchi |
|
dbp:stdinchikey |
|
dbp:synonyms |
|
dbp:unii |
|
dbp:width |
|
dbp:wikiPageUsesTemplate | |
dcterms:subject | |
rdf:type | |
rdfs:comment |
|
rdfs:label |
|
owl:sameAs | |
prov:wasDerivedFrom | |
foaf:depiction | |
foaf:isPrimaryTopicOf | |
is dbo:wikiPageRedirects of | |
is dbo:wikiPageWikiLink of | |
is foaf:primaryTopic of |